Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalEarly Phase 1

Feasibility and Safety of Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors

NCT ID: NCT05645523Sponsor: St. Jude Children's Research HospitalLast updated: 2026-05-04

Summary

The purpose of the study is to find out the usefulness and safety of a dye called Indocyanine Green (ICG for short). This dye will be used to help the surgeon find lymph nodes draining solid tumors inside the abdomen that need to be removed. This may also help the surgeon to find if the cancer has moved to other lymph nodes outside of the known area. Primary Objectives * To determine the percentage of patients in whom Indocyanine Green (ICG)-guided sentinel lymph node (SLN) mapping was successful at the time of retroperitoneal lymph node dissection for staging of visceral solid tumors. * To determine the percentage of patients with grade 3 or higher adverse events related to ICG use.

Detailed description

During surgery, participants will be given the dye to help the doctor see the lymph nodes to be removed. Pictures or a video of the procedure will be done. The number of lymph nodes removed will be recorded. After surgery, the lymph nodes will be examined. Participants will be followed for up to 24 hours after surgery to determine if there were any side effects from the dye.

Arms & interventions

  • DrugIndocyanine Green

    Given in to the vein (IV)

Outcome measures

Primary

  • Percentage of patients in whom Indocyanine Green (ICG)-guided sentinel lymph node (SLN) mapping was successful

    The estimated percentage of ICG identification and its confidence interval (CI) based on the Pearson-Klopper method exact method will be calculated.

    Time frame: During surgery (Intraoperatively)

  • Percentage of patients with grade 3 or higher adverse events related to ICG use

    Adverse Events will be captured from the time of ICG administration to 24 hours post-surgery. Adverse Events will be graded by this scale: the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: From the time of ICG administration to 24 hours after surgery (post-surgery)

Eligibility criteria

Sex: AllAge: Up to 20 YearsHealthy volunteers: No
Inclusion Criteria: * Any patient under the age of 21 years with visceral pediatric solid tumor suspected to be Wilms tumor or para-testicular rhabdomyosarcoma requiring retroperitoneal lymph node dissection. Exclusion Criteria: * Subjects with a history of iodide allergies. * Inability or unwillingness of research participant or legal guardian/representative to give written informed consent. * Pregnant female. * Patients with extensive prior surgery at the primary site or nodal basin expected to affect the lymphatic drainage.

Study locations (3)

Lurie Children's Hospital

Chicago, Illinois, 60611

Recruiting
Timothy Lautz, MD · Contact
312-227-4736tlautz@luriechildrens.org
Timothy Lautz, MD · Principal Investigator

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, 15224

Recruiting
Marcus Malek, MD · Contact
412-692-7280marcus.malek@chp.edu
Marcus Malek, MD · Principal Investigator

St. Jude Children's Research Hospital

Memphis, Tennessee, 38105

Recruiting
Andrew Davidoff, MD · Contact
888-226-4343referralinfo@stjude.org
Andrew Davidoff, MD · Principal Investigator